{"id":"ciramadol","rwe":[{"pmid":"2723108","year":"1989","title":"Effects of liver disease on the disposition of ciramadol in humans.","finding":"","journal":"Journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"2572952","year":"1989","title":"The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter.","finding":"","journal":"Life sciences","studyType":"Clinical Study"},{"pmid":"3052729","year":"1988","title":"A single dose study of a new analgesic. Ciramadol.","finding":"","journal":"Journal (Canadian Dental Association)","studyType":"Clinical Study"},{"pmid":"3593906","year":"1987","title":"The effect of food on ciramadol bioavailability in normal subjects.","finding":"","journal":"Biopharmaceutics & drug disposition","studyType":"Clinical Study"},{"pmid":"3559982","year":"1987","title":"Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.","finding":"","journal":"The Journal of pharmacology and experimental therapeutics","studyType":"Clinical Study"}],"tags":[{"label":"ciramadol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mu-type opioid receptor","category":"target"},{"label":"OPRM1","category":"gene"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["ciramadol","ciramadol hydrochloride","WY15705","WY-15705","ciramadol HCl"],"offLabel":[],"synonyms":["ciramadol","ciramadol hydrochloride","WY15705","WY-15705","ciramadol HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Mu-type opioid receptor","targets":[{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"}],"modality":"Small Molecule","drugClass":"ciramadol","explanation":"Imagine your brain has a volume control for pain. Mu-type opioid receptors are like the volume knob. When CIRAMADOL binds to these receptors, it turns down the volume, making pain feel less intense. This can help relieve pain in people who are suffering from it.","oneSentence":"CIRAMADOL works by activating the mu-type opioid receptors in the brain, which helps to reduce pain perception.","technicalDetail":"CIRAMADOL acts as a mu-type opioid receptor agonist, binding to the receptor's G-protein coupled receptor (GPCR) and activating the downstream signaling pathways, ultimately leading to the inhibition of pain transmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3713","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CIRAMADOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:02:57.789082","biosimilars":[],"competitors":[{"drugName":"alfentanil","drugSlug":"alfentanil","fdaApproval":"1986-12-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"alvimopan","drugSlug":"alvimopan","fdaApproval":"2008-05-20","patentExpiry":"Feb 12, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"anileridine","drugSlug":"anileridine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"buprenorphine","drugSlug":"buprenorphine","fdaApproval":"1981-12-29","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"butorphanol","drugSlug":"butorphanol","fdaApproval":"1978-08-22","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ciramadol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alfentanil","brandName":"alfentanil","genericName":"alfentanil","approvalYear":"1986","relationship":"same-target"},{"drugId":"alvimopan","brandName":"alvimopan","genericName":"alvimopan","approvalYear":"2008","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"anileridine","brandName":"anileridine","genericName":"anileridine","approvalYear":"","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"buprenorphine","brandName":"buprenorphine","genericName":"buprenorphine","approvalYear":"1981","relationship":"same-target"},{"drugId":"butorphanol","brandName":"butorphanol","genericName":"butorphanol","approvalYear":"1978","relationship":"same-target"},{"drugId":"cannabidiol","brandName":"cannabidiol","genericName":"cannabidiol","approvalYear":"2018","relationship":"same-target"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"9NQ109OW0G","CHEBI":"CHEBI:135016","INN_ID":"4464","UMLSCUI":"C0055779","ChEMBL_ID":"CHEMBL2104132","KEGG_DRUG":"D03523","PUBCHEM_CID":"44463","SECONDARY_CAS_RN":"63323-46-6","MESH_SUPPLEMENTAL_RECORD_UI":"C018273"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.85 hours","clearance":"2.2 mL/min/kg"},"publicationCount":37,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"1989 Mar","pmid":"2723108","title":"Effects of liver disease on the disposition of ciramadol in humans.","journal":"Journal of clinical pharmacology"},{"date":"1989","pmid":"2572952","title":"The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter.","journal":"Life sciences"},{"date":"1988 Sep","pmid":"3052729","title":"A single dose study of a new analgesic. Ciramadol.","journal":"Journal (Canadian Dental Association)"},{"date":"1987 May-Jun","pmid":"3593906","title":"The effect of food on ciramadol bioavailability in normal subjects.","journal":"Biopharmaceutics & drug disposition"},{"date":"1987 Mar","pmid":"3559982","title":"Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.","journal":"The Journal of pharmacology and experimental therapeutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CIRAMADOL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CIRAMADOL is a small molecule drug that targets the mu-type opioid receptor. It is classified as a ciramadol, but its commercial status and approved indications are unknown. The half-life of CIRAMADOL is approximately 3.85 hours, but its bioavailability and off-patent status are not available. As a mu-type opioid receptor agonist, CIRAMADOL works by binding to and activating these receptors, which are involved in pain modulation. Further information on its development, approval, and commercialization is needed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}